How to buy Hutchison China MediTech stock

Hutchison China MediTech Limited is a biotechnology business based in the US. Hutchison China MediTech shares (HCM) are listed on the NASDAQ and all prices are listed in US Dollars. Hutchison China MediTech employs 853 staff and has a trailing 12-month revenue of around USD$209.5 million.

How to buy shares in Hutchison China MediTech

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Hutchison China MediTech. Find the stock by name or ticker symbol: HCM. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Hutchison China MediTech reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Hutchison China MediTech, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Hutchison China MediTech. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Hutchison China MediTech share price

Use our graph to track the performance of HCM stocks over time.

Hutchison China MediTech shares at a glance

• Key figures

Information last updated 2021-02-23.

52-week range	USD$14.74 - USD$37
50-day moving average	USD$34.4232
200-day moving average	USD$32.3768
Wall St. target price	USD$39.6
PE ratio	17.6909
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.66

Buy Hutchison China MediTech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Hutchison China MediTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Hutchison China MediTech Limited by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Hutchison China MediTech financials

Revenue TTM	USD$209.5 million
Gross profit TTM	USD$-93,452,000
Return on assets TTM	-18.68%
Return on equity TTM	-29.31%
Profit margin	-52.68%
Book value	$2.49
Market capitalisation	USD$4.5 billion

TTM: trailing 12 months

Shorting Hutchison China MediTech shares

There are currently 831,246 Hutchison China MediTech shares held short by investors – that's known as Hutchison China MediTech's "short interest". This figure is 15.7% down from 985,637 last month.

There are a few different ways that this level of interest in shorting Hutchison China MediTech shares can be evaluated.

Hutchison China MediTech's "short interest ratio" (SIR)

Hutchison China MediTech's "short interest ratio" (SIR) is the quantity of Hutchison China MediTech shares currently shorted divided by the average quantity of Hutchison China MediTech shares traded daily (recently around 225882.06521739). Hutchison China MediTech's SIR currently stands at 3.68. In other words for every 100,000 Hutchison China MediTech shares traded daily on the market, roughly 3680 shares are currently held short.

However Hutchison China MediTech's short interest can also be evaluated against the total number of Hutchison China MediTech shares, or, against the total number of tradable Hutchison China MediTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hutchison China MediTech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Hutchison China MediTech shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Hutchison China MediTech shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hutchison China MediTech.

Find out more about how you can short Hutchison China MediTech stock.

Have Hutchison China MediTech's shares ever split?

Hutchison China MediTech's shares were split on 30 May 2019.

Hutchison China MediTech share price volatility

Over the last 12 months, Hutchison China MediTech's shares have ranged in value from as little as $14.74 up to $37. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hutchison China MediTech's is 0.5915. This would suggest that Hutchison China MediTech's shares are less volatile than average (for this exchange).

Hutchison China MediTech overview

Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Frequently asked questions

• What percentage of Hutchison China MediTech is owned by insiders or institutions?

  Currently 6.263% of Hutchison China MediTech shares are held by insiders and 33.784% by institutions.

• How many people work for Hutchison China MediTech?

  Latest data suggests 853 work at Hutchison China MediTech.

• When does the fiscal year end for Hutchison China MediTech?

  Hutchison China MediTech's fiscal year ends in December.

• Where is Hutchison China MediTech based?

  Hutchison China MediTech's address is: Cheung Kong Center, Central, Hong Kong

• What is Hutchison China MediTech's ISIN number?

  Hutchison China MediTech's international securities identification number is: US44842L1035

• What is Hutchison China MediTech's CUSIP number?

  Hutchison China MediTech's Committee on Uniform Securities Identification Procedures number is: 44842L103